Apolipoprotein L1 (APOL1) and Nephropathy
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Yael Szyferman, Alanis | |
| dc.contributor.author | Kleppe, Soledad | |
| dc.contributor.author | Cristiano, Fabrizio | |
| dc.contributor.author | Conde-Manotas, Juan C. | |
| dc.contributor.author | Cadena-Bonfanti, Andrés | |
| dc.contributor.author | Aroca-Martinez, Gustavo | |
| dc.contributor.author | Musso, Carlos G. | |
| dc.date.accessioned | 2026-03-18T14:50:43Z | |
| dc.date.available | 2026-03-18T14:50:43Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Introduction. End-stage renal disease exhibits a disproportionate prevalence among Black individuals and older adults within the United States and worldwide. A significant genetic contributor to this disparity is the Apolipoprotein L1 (APOL1) gene, found exclusively in populations of African ancestry. Materials and Method. We aim to perform a narrative review regarding the current understanding of APOL1 and its complex role in kidney disease pathogenesis. Results. The G1 and G2 APOL1 risk alleles are strongly associated with an elevated risk for non-diabetic chronic kidney disease (CKD), including hypertensive nephropathy, focal segmental glomerulosclerosis, and HIV-associated nephropathy, in individuals who are homozygous or compound heterozygous for these variants. While 10-15% of African Americans carry two APOL1 risk alleles, approximately 80% remain disease-free, suggesting incomplete penetrance and the involvement of additional risk factors. In this condition, renal damage could be induced through different mechanisms such as altered cellular ion transport, mitochondrial dysfunction, and the requirement for additional stressors or “second hits”. Conclusion. The increased susceptibility to end-stage renal disease (ESRD) in individuals of African ancestry is influenced by variations in the APOL1 gene. | eng |
| dc.format.mimetype | ||
| dc.identifier.doi | https://doi.org/10.69097/43-01-2026-05 | |
| dc.identifier.issn | 17245990 (electrónico) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/17422 | |
| dc.identifier.url | https://giornaleitalianodinefrologia.it/en/2026/02/43-01-2026-05/ | |
| dc.language.iso | eng | |
| dc.publisher | Società Italiana di Nefrologia | Ita |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.source | Giornale Italiano di Nefrologia | Ita |
| dc.source | G Ital Nefrol | Ita |
| dc.source | Vol. 1 No. 43 Año 2026 | spa |
| dc.subject.keywords | Apolipoprotein L1 | eng |
| dc.subject.keywords | Kidney diseases | eng |
| dc.subject.keywords | Genetics | eng |
| dc.title | Apolipoprotein L1 (APOL1) and Nephropathy | eng |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Chen TK, Coresh J, Daya N, Ballew SH, Tin A, Crews DC, Grams ME. Race, APOL1 Risk Variants, and Clinical Outcomes among Older Adults: The ARIC Study. J Am Geriatr Soc. 2021 Jan;69(1):155-163. https://doi.org/10.1111/jgs.16797. | eng |
| dcterms.references | Perez JPZ, Torres JV, Suárez MRU, Ochoa MPP, Hoyos GA, Henao OO. Modelo ideal de nefroprevención para Colombia: Ideal nefroprevention model for Colombia. Rev Colomb Nefrol. 2021 Aug 18;8(3):e431– https://doi.org/10.22265/acnef.8.3.431. | eng |
| dcterms.references | Duran CE, Ramírez A, Posada JG, Schweineberg J, Mesa L, Pachajoa H, Estacio M, Manzi E, Aros V, Díaz L, Garcia VH. Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country. Int J Nephrol. 2019 Dec 18;2019:7076326. https://doi.org/10.1155/2019/7076326. Erratum in: Int J Nephrol. 2020 Nov 17;2020:8706297. https://doi.org/10.1155/2020/8706297. | eng |
| dcterms.references | Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011 May;11(5):1025-30. https://doi.org/10.1111/j.1600-6143.2011.03513.x. | eng |
| dcterms.references | Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011 Nov;22(11):2129-37. https://doi.org/10.1681/ASN.2011040388. | eng |
| dcterms.references | Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010 Aug 13;329(5993):841-5. https://doi.org/10.1126/science.1193032. | eng |
| dcterms.references | Freedman BI, Langefeld CD, Turner J, Núñez M, et al. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int. 2012 Oct;82(7):805-11. https://doi.org/10.1038/ki.2012.217. | eng |
| dcterms.references | Beckerman P, Susztak K. APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease. Trends Mol Med. 2018 Aug;24(8):682-695. https://doi.org/10.1016/j.molmed.2018.05.008. | eng |
| dcterms.references | Markowitz GS, Nasr SH, Stokes MB, D’Agati VD. Treatment with IFN-α, -ß, or -δ is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010 Apr;5(4):607-15. https://doi.org/10.2215/CJN.07311009. Epub 2010 Mar 4. Erratum in: Clin J Am Soc Nephrol. 2010 Jul;5(7):1353. | eng |
| dcterms.references | Vivante A. Genetics of Chronic Kidney Disease. N Engl J Med. 2024 Aug 15;391(7):627-639. https://doi.org/10.1056/NEJMra2308577. PMID: 39141855. | eng |
| dcterms.references | Gbadegesin RA, Ulasi I, Ajayi S, Raji Y, et al; H3Africa Kidney Disease Research Network. APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans. N Engl J Med. 2025 Jan 16;392(3):228-238. https://doi.org/10.1056/NEJMoa2404211. | eng |
| dcterms.references | Bruggeman LA, Azhibekov T, O’Toole JF. Moving Toward a Common Pathogenic Mechanism and Therapeutic Targets for APOL1 Nephropathies. Am J Kidney Dis. 2022 Jun;79(6):901-903. https://doi.org/10.1053/j.ajkd.2022.02.011. | eng |
| dcterms.references | Cubedo J, Padró T, Alonso R, Mata P, Badimon L. ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia. J Lipid Res. 2016 Jun;57(6):1059-73. https://doi.org/10.1194/jlr.P061598. | eng |
| dcterms.references | Itoku A, Isaac J, Wilson S, Reidy K, Kaskel F. APOL1 Nephropathy Risk Variants Through the Life Course: A Review. Am J Kidney Dis. 2024 Jul;84(1):102-110. https://doi.org/10.1053/j.ajkd.2023.12.014. | eng |
| dcterms.references | Egbuna O, Chertow GM. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. Reply. N Engl J Med. 2023 Jun 29;388(26):2491. https://doi.org/10.1056/NEJMc2304780. PMID: 37379148 | eng |
| dcterms.references | Aghajan M, Booten SL, Althage M, Hart CE, wt al. Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice. JCI Insight. 2019 Jun 20;4(12):e126124. https://doi.org/10.1172/jci.insight.126124. | eng |
| dcterms.references | Wu J, Raman A, Coffey NJ, Sheng X, et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J Clin Invest. 2021 Oct 15;131(20):e136329. https://doi.org/10.1172/JCI136329. PMID: 34651582; PMCID: PMC8516463 | eng |
| dcterms.references | Nystrom SE, Li G, Datta S, Soldano KL, Silas D, Weins A, Hall G, Thomas DB, Olabisi OA. JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids. JCI Insight. 2022 Jun 8;7(11):e157432. https://doi.org/10.1172/jci.insight.157432. | eng |
| dcterms.references | Freedman BI, Moxey-Mims MM, Alexander AA, et al. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale. Kidney Int Rep. 2019 Dec 13;5(3):278-288. https://doi.org/10.1016/j.ekir.2019.11.022. | eng |
| dcterms.references | Chang JH, Husain SA, Santoriello D, Stokes MB, Miles CD, Foster KW, Li Y, Dale LA, Crew RJ, Cohen DJ, Kiryluk K, Gharavi AG, Mohan S. Donor’s APOL1 Risk Genotype and “Second Hits” Associated With De Novo Collapsing Glomerulopathy in Deceased Donor Kidney Transplant Recipients: A Report of 5 Cases. Am J Kidney Dis. 2019 Jan;73(1):134-139. https://doi.org/10.1053/j.ajkd.2018.05.008. | eng |
| dcterms.references | Merle JL, Kuo MC, Gacki-Smith J, Agrawal A, Friedewald J, Gordon EJ, Smith JD. Contextual factors of implementing APOL1 genetic testing into living kidney donor clinical evaluation. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Jul;68(7):758-768. https://doi.org/10.1007/s00103-025-04068-8. Epub 2025 Jun 11. PMID: 40498120; PMCID: PMC12254160. | eng |
| dcterms.references | Ojo AO, Adu D, Bramham K, Freedman BI, Gbadegesin RA, Ilori TO, Jefferson N, Olabisi OA, Susztak K, Young BA, Cheung M, King JM, Grams ME, Jadoul M, Ulasi II; Conference Participants. APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025 Jun 23:S0085-2538(25)00429-6. https://doi.org/10.1016/j.kint.2025.05.017. Epub ahead of print. PMID: 40582702 | eng |
| dcterms.references | Bruggeman LA, Azhibekov T, O’Toole JF. Moving Toward a Common Pathogenic Mechanism and Therapeutic Targets for APOL1 Nephropathies. Am J Kidney Dis. 2022 Jun;79(6):901-903. https://doi.org/10.1053/j.ajkd.2022.02.011. Epub 2022 Feb 28. PMID: 35240248 | eng |
| dcterms.references | Freedman BI, Limou S, Ma L, Kopp JB. APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD. Am J Kidney Dis. 2018 Nov;72(5 Suppl 1):S8-S16. https://doi.org/10.1053/j.ajkd.2018.06.020. | eng |
| dcterms.references | Rasmussen LV, Agrawal AH, Botsford P, Powers A, Schnoebelen J, Xinos S, Harper G, Thanner J, McCabe S, Moore S, Wicklund CA, Duquette D, Gordon EJ. Challenges of Integrating APOL1 Genetic Test Results into the Electronic Health Record. Appl Clin Inform. 2023 Mar;14(2):321-325. https://doi.org/10.1055/s-0043-1767680. Epub 2023 Apr 26. PMID: 37186083; PMCID: PMC10132929. | eng |
| dcterms.references | Elliott MD, Vena N, Marasa M, Cocchi E, Bheda S, Bogyo K, et al; CureGN Consortium. Increased risk of kidney failure in patients with genetic kidney disorders. J Clin Invest. 2024 Sep 3;134(17):e178573. https://doi.org/10.1172/JCI178573. PMID: 39225089; PMCID: PMC11364380. | eng |
| dcterms.references | https://www.kidney.org/press-room/national-kidney-foundation-unveils-recommendations-genetic-testing-kidney-disease. | eng |
| dcterms.references | Dahl NK, Bloom MS, Chebib FT, Clark D, Westemeyer M, et al. The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults with Chronic Kidney Disease. J Am Soc Nephrol. 2023 Dec 1;34(12):2039-2050. https://doi.org/10.1681/ASN.0000000000000249. | eng |
| dcterms.references | Lin MR, Wu IW, Chou WH, Lin YF, Hung KY, Kojima K, Shido K, Kinoshita K, Chang WC, Wu MS. Whole exome sequencing and polygenic risk assessment for kidney functions and clinical management in both hospital-based cohort and population-based Asian cohorts. J Biomed Sci. 2025 Aug 6;32(1):72. https://doi.org/10.1186/s12929-025-01168-0. PMID: 40770708; PMCID: PMC12330128. | eng |
| dcterms.references | Naama Elefant, Maddalena Marasà, Hila Milo Rasouly. Beyond Kidney Genes: Broad Clinical Implications of Genetic Testing for Nephrology Patients. Seminars in Nephrology, Volume 45, Issue 4, 151660. https://doi.org/10.1016/j.semnephrol.2025.151660. | eng |
| dcterms.references | Franceschini, D.L. Feldman, et al. Advancing Genetic Testing in Kidney Diseases: Report From a National Kidney Foundation Working Group. American Journal of Kidney Diseases, Volume 84, Issue 6, 751 – 766. https://doi.org/10.1053/j.ajkd.2024.05.010. | eng |
| dcterms.references | Abraham W Aron, Neera K Daahl. Clinical Genetic Testing in Nephrology: Core Curriculum 2024. American Journal of Kidney Diseases, Volume 84, Issue 5, 632 – 645. https://doi.org/10.1053/j.ajkd.2024.05.011. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |